Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. is a global pharmaceutical company headquartered in San Diego, California, focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's mission is to transform the treatment of endocrine conditions by leveraging its expertise in G-protein coupled receptors (GPCRs) to develop innovative small-molecule therapies.

Crinetics' lead commercial product is PALSONIFY® (paltusotine), a once-daily oral somatostatin receptor agonist approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option. The company maintains a robust pipeline, including late-stage investigational candidates such as atumelnant, which is in development for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate targeting somatostatin receptor 2 (SST2)-expressing neuroendocrine tumors and other solid tumors.

In a significant recent development, Vertex Pharmaceuticals announced an agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals for approximately $10 billion in cash, a transaction anticipated to close in the third quarter of 2026. This acquisition aims to integrate Crinetics' commercialized and pipeline assets into Vertex's portfolio, further advancing therapies for serious, rare endocrine disorders. R. Scott Struthers, Ph.D., co-founder, serves as the Chief Executive Officer, leading the company's strategic direction.